Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

AMICUS T Form 4 July 17, 20	THERAPEUTICS	INC	5									
FORM									OMB	APPROVAL		
-	SECURITIES AND EXCHANGE COMMISSIO Washington, D.C. 20549						OMB Number:	3235-0287				
Check t if no los subject Section Form 4 Form 5 obligati may co <i>See</i> Inst 1(b).	nger to 16. or Filed pu ons ntinue.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							burden he response	Estimated average burden hours per response 0.5		
(Print or Type	Responses)											
GLAXOSMITHKLINE PLC Symb AMI			Symbol	CUS THERAPEUTICS INC				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
980 GREAT WEST ROAD 0' (Street) 4.			3. Date of Earliest Transaction (Month/Day/Year) 07/17/2012					DirectorOfficer (give titleOther (specify below)Other (specify below)				
				nendment, I onth/Day/Ye	Date Original ar)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
BRENTFO MIDDLES	ORD SEX,, X0 TW8 9G	S						Form filed by M Person	Aore than One	Reporting		
(City)	(State)	(Zip)	Tal	ble I - Non-	-Derivative Se	curiti	es Acai	uired, Disposed of	f. or Benefic	ially Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		d Date, if	3.		Acquir of (D)	_	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	07/17/2012			Р	2,949,581	A	\$ 6.3	9,815,825	I	By Corporation		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	5. iorNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	Date	Amou Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
				Code V	7 (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

ner

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
F 8	Director	10% Owner	Officer	Oth			
GLAXOSMITHKLINE PLC 980 GREAT WEST ROAD BRENTFORD MIDDLESEX,, X0 TW8 9GS		Х					
Signatures							
/s/ Victoria A. Whyte, Company Secretary	07/17/2	012					
**Signature of Reporting Person	Date						
Evaluation of Decanonace							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Shares of Common Stock are held of record by Glaxo Group Limited, which is an indirect wholly-owned subsidiary of Reporting Person.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.